Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Novo Holdings
AddedFeb 13, 2024
UpdatedJun 28, 2026
Novo Holdings

Novo Holdings

Operating

Danish-based Novo Holdings A/S, a wholly-owned subsidiary of the Novo Nordisk Foundation.

Location
Hellerup, Capital Region of Denmark, DK
Founded
1999
Firm
Compare
Portfolio
Employees
News
Website

Investments

Elo Life Systems
Elo Life Systems

Total Raised

$56.5M

Rounds

3

Series A$20.5MJanuary 2024
Series A$24.5MFebruary 2023
Cleveland Diagnostics
Cleveland Diagnostics

Total Raised

$111M

Rounds

8

Private Equity$75MJanuary 2024
Revagenix
Revagenix

Total Raised

$4M

Rounds

2

Series BJanuary 2024
Claris Biotherapeutics
Claris Biotherapeutics

Total Raised

$101.5M

Rounds

3

Series A$57MJanuary 2024
OnCusp Therapeutics
OnCusp Therapeutics

Total Raised

$125M

Rounds

2

Series A$100MJanuary 2024
Nalu Medical
Nalu Medical

Total Raised

$180.9M

Rounds

3

Series E$65MJanuary 2024
EnergyRe
EnergyRe
Private Equity

Total Raised

$1.2B

Rounds

1

Private Equity$1.2BDecember 2023
Terremoto Biosciences
Terremoto Biosciences

Total Raised

$250M

Rounds

2

Series B$175MNovember 2023
MapLight Therapeutics
MapLight Therapeutics

Total Raised

$268.1M

Rounds

4

Series C$225MOctober 2023
Avalyn Pharma
Avalyn Pharma

Total Raised

$272.5M

Rounds

3

Series C$175MSeptember 2023
Clever Care Health Plan
Clever Care Health Plan

Total Raised

$139M

Rounds

5

Series C$42MMarch 2023
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Post Ipo Equity$53.6MFebruary 2023
Metagenomi
Metagenomi

Total Raised

$457M

Rounds

7

Series B$100MJanuary 2023
Series B$175MJanuary 2022
Iecure
Iecure

Total Raised

$115M

Rounds

2

Series A$65MNovember 2022
Breye Therapeutics
Breye Therapeutics

Total Raised

$4M

Rounds

2

Seed$4MNovember 2022
Kate Farms
Kate Farms

Total Raised

$188M

Rounds

5

Series C$75MSeptember 2022
Vestaron
Vestaron

Total Raised

$264.9M

Rounds

15

Series C$10MAugust 2022
Series C$82MMay 2022
Inspirna
Inspirna

Total Raised

$144.6M

Rounds

6

Series D$55.1MJuly 2022
Nuvig Therapeutics
Nuvig Therapeutics

Total Raised

$47M

Rounds

1

Series A$47MMay 2022
Invetx
Invetx

Total Raised

$85.8M

Rounds

3

Series B$60.5MMay 2022
Rondo Therapeutics
Rondo Therapeutics

Total Raised

$67M

Rounds

1

Series A$67MMarch 2022
Biomason
Biomason

Total Raised

$95M

Rounds

7

Series C$65MFebruary 2022